Update on combined immunotherapy for the treatment of advanced renal cell carcinoma

被引：28

作者：

Gebrael, Georges ^{[1
]}

Sahu, Kamal Kant ^{[1
]}

Agarwal, Neeraj ^{[1
]}

Maughan, Benjamin L. L. ^{[1
,2
]}

机构：

[1] Univ Utah, Huntsman Canc Inst, Dept Internal Med, Div Oncol, Salt Lake City, UT USA

[2] Univ Utah NCI CCC, Huntsman Canc Inst, 2000 Circle Hope Dr,Suite 5726, Salt Lake City, UT 84112 USA

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2023年 / 19卷 / 01期

关键词：

Immune checkpoint inhibitors; renal cell carcinoma; immunotherapy; PD-1; PD-L1; PLUS AXITINIB; OPEN-LABEL; SUNITINIB; NIVOLUMAB; CABOZANTINIB;

D O I：

10.1080/21645515.2023.2193528

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

There has been substantial evolution in the treatment of metastatic renal cell carcinoma with notable changes in the first-line setting. Currently, doublet combination therapy with either two immune checkpoint inhibitors or a combination of an immune checkpoint and tyrosine kinase inhibitor is considered the standard of care. The doublet combination therapies have demonstrated significantly improved clinical outcomes. A recently conducted trial (COSMIC-313) showed superior efficacy with a triplet combination of cabozantinib, nivolumab, and ipilimumab when compared to a placebo, nivolumab, and ipilimumab but at the cost of additional toxicity. Many other combination treatments, such as pembrolizumab plus lenvatinib plus belzutifan (NCT04976634), are being investigated, possibly leading to more options in the first-line setting in the future.

引用

页数：8

共 37 条

[1]

[Anonymous], 2024, BioRender.com/g36g809

[2] Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) [J].

Atkins, Michael B. ;

Jegede, Opeyemi A. ;

Haas, Naomi B. ;

McDermott, David F. ;

Bilen, Mehmet A. ;

Stein, Mark ;

Sosman, Jeffrey A. ;

Alter, Robert ;

Plimack, Elizabeth R. ;

Ornstein, Moshe ;

Hurwitz, Michael ;

Peace, David J. ;

Signoretti, Sabina ;

Denize, Thomas ;

Cimadamore, Alessia ;

Wu, Catherine J. ;

Braun, David ;

Einstein, David ;

Catalano, Paul J. ;

Hammers, Hans .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) :2913-+

[3]

Burotto M, 2023, J CLIN ONCOL, V41

[4] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial [J].

Cella, David ;

Gruenwald, Viktor ;

Escudier, Bernard ;

Hammers, Hans J. ;

George, Saby ;

Nathan, Paul ;

Grimm, Marc-Oliver ;

Rini, Brian, I ;

Doan, Justin ;

Ivanescu, Cristina ;

Paty, Jean ;

Mekan, Sabeen ;

Motzer, Robert J. .

LANCET ONCOLOGY, 2019, 20 (02) :297-310

[5] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[6]

Choueiri TK, 2020, ANN ONCOL, V31, P1030, DOI [10.1016/j.annonc.2020.04.010, 10.1016/j.annoc.2020.04.010]

[7] Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial [J].

Choueiri, Toni K. ;

Halabi, Susan ;

Sanford, Ben L. ;

Hahn, Olwen ;

Michaelson, M. Dror ;

Walsh, Meghara K. ;

Feldman, Darren R. ;

Olencki, Thomas ;

Picus, Joel ;

Small, Eric J. ;

Dakhil, Shaker ;

George, Daniel J. ;

Morris, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06) :591-+

[8] New Therapeutic Interventions for Kidney Carcinoma: Looking to the Future [J].

Dell'Atti, Lucio ;

Bianchi, Nicoletta ;

Aguiari, Gianluca .

CANCERS, 2022, 14 (15)

[9]

Graham Jeffrey, 2018, Am Soc Clin Oncol Educ Book, V38, P330, DOI 10.1200/EDBK_201215

[10]

Grimm MO, 2019, ANN ONCOL, V30, P892

← 1 2 3 4 →